Fulcrum Therapeutics reduced its workforce, letting go 48 of 57 full-time employees following disclosures in an SEC filing. The company’s restructuring comes as it attempts to preserve runway after earlier setbacks and amid a tighter environment for clinical-stage funding. The move highlights a recurring pattern in biotech: teams reduce operating costs first, then pursue the remaining critical path activities—often including additional capital planning, development reprioritization, or partner talks. Separately, Seres extended its runway into 2027, suggesting diverging strategies among microbiome and clinical-stage players. For Fulcrum, the key near-term question will be how quickly the company can translate the remaining resources into milestones that can support continued financing. The staffing cuts are a tangible signal for employees and investors that liquidity and clinical timelines remain decisive in the current market.